CVM
AMEXCEL-SCI Corporation
Healthcare · Biotechnology
Price History
Learn Why It Moved
Educational concepts related to this stock
Low Float
This stock has a relatively low number of shares available for trading, which can amplify price movements.
Selling Pressure
A significant downward move. Understanding risk management and stop losses is critical here.
Biotech Catalyst
Biotech stocks are often driven by FDA approvals, trial results, and regulatory news. Learn how binary catalysts work.
Insider Activity
Check if insiders have been buying or selling. Insider buying is one of the strongest signals in small cap trading.
Dilution Risk
Check SEC filings for active shelf registrations. Dilution is the #1 risk in small cap trading.
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.